Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer
XBiotech Inc. (XBIT)
Last xbiotech inc. earnings: 8/9 03:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
xbiotech.com/about/investors.html
Company Research
Source: GlobeNewswire
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix™, to be used in combination with cytotoxic anti-cancer agents. Natrunix™ specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of healthy tissue. The anti-inflammatory activity of Natrunix™ is also being evaluated for its ability to reduce the toxicity and injury caused by the cytotoxic anti-cancer agents themselves. XBiotech’s pancreatic cancer program, 1-BETTER, launched with a randomized, double-blind, placebo-controlled Phase 1-2 study, allows the Company to evaluate dose levels, drug interaction and anti-cancer activity for Natrunix™. Dr. Musher is Medical Director of Medical Oncology at Dan L. Duncan Comprehensive Canc
Show less
Read more
Impact Snapshot
Event Time:
XBIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XBIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBiotech Inc. news events
Weekly update
A roundup of the hottest topics
XBIT
Sec Filings
- 5/10/24 - Form 10-Q
- 5/1/24 - Form ARS
- 5/1/24 - Form DEFA14A
- XBIT's page on the SEC website